Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Haematologica. 2016 Jul;101(7):e280-3. doi: 10.3324/haematol.2016.142695. Epub 2016 Apr 7.
No abstract available

Keywords: cytogenetics and molecular genetics; myelodysplastic syndromes; red cells.

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disease-Free Survival
  • Female
  • Hematinics / administration & dosage*
  • Humans
  • Male
  • Mutation*
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics
  • Myelodysplastic Syndromes* / mortality
  • Risk Factors
  • Survival Rate

Substances

  • Hematinics